.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,856,493

« Back to Dashboard

Details for Patent: 5,856,493

Title: Process for making novel form of paroxeting hydrochloride anhydrate
Abstract:The present invention relates to paroxetine hydrochloride anhydrate substantially free of bound propan-2-ol, several forms of the above, processes for preparing the above, new intermediates useful in preparing the above and methods of treating and/or preventing certain diseases by administering the compounds of the invention to a patient in need thereof.
Inventor(s): Ward; Neal (Crowborough, GB2), Jacewicz; Victor Witold (Tunbridge Wells, GB2)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Filing Date:Feb 29, 1996
Application Number:08/608,782
Claims:1. A process for preparing paroxetine hydrochloride anhydrate Form C which process comprises seeding a solution of paroxetine hydrochloride in butan-1-ol with a seed crystal of paroxetine hydrochloride anhydrate Form B whereby crystallization of paroxetine hydrochloride anhydrate Form C occurs,

wherein paroxetine hydrochloride anhydrate Form C comprises the following characteristics: a melting point of about 164.degree. C.; IR bands at about 540, 574, 615, 674, 720, 760, 779, 802, 829, 840, 886, 935, 965, 984, 1007, 1034, 1092, 1109, 1139, 1183, 1218, 1240, 1263, 1280, 1507, 1540, 1558, 1598, and 1652 cm.sup.-1 ; a DSC maximum endotherm, measured at 10.degree. C. per minute, of about 161.degree. C. in both open and closed pans; characteristic X-ray diffractogram peaks at about 10.1, 12.1, 13.1, 14.3 degrees 2 theta; characteristic solid state .sup.13 C-NMR spectrum peaks at about 154.0, 148.5, 143.4, and 140.4 ppm, and

paroxetine hydrochloride anhydrate Form B comprises the following characteristics: a melting point of about 138.degree. C.; IR bands at about 538, 574, 614, 675, 722, 762, 782, 815, 833, 884, 925, 938, 970, 986, 1006, 1039, 1069, 1094, 1114, 1142, 1182, 1230, 1274, 1304, 1488, 1510, 1574, 1604, and 1631 cm.sup.-1 ; a DSC maximum endotherm, measured at 10.degree. C. per minute, of about 137.degree. C. in both open and closed pans; characteristic X-ray diffractogram peaks at about 5.7, 11.3, 12.4, and 14.3 degrees 2 theta; characteristic solid state .sup.13 C-NMR spectrum peaks at about 154.6, 148.3, 150.1, 141.7, 142.7, and 139.0 ppm.

2. The process of claim 1 wherein the paroxetine hydrochloride in butan-1-ol is prepared by azeotropic distillation of paroxetine hydrochloride hemihydrate in toluene to remove the toluene, while replacing the toluene with butan-1-ol.

3. A process for preparing paroxetine hydrochloride anhydrate Form C which process comprises seeding a solution of paroxetine hydrochloride in ethyl acetate with a seed crystal of paroxetine hydrochloride anhydrate Form A whereby crystallization of paroxetine hydrochloride anhydrate Form C occurs,

wherein paroxetine hydrochloride anhydrate Form C comprises the following characteristics: a melting point of about 164.degree. C.; IR bands at about 540, 574, 615, 674, 720, 760, 779, 802, 829, 840, 886, 935, 965, 984, 1007, 1034, 1092, 1109, 1139, 1183, 1218, 1240, 1263, 1280, 1507, 1540, 1558, 1598, and 1652 cm.sup.-1 ; a DSC maximum endotherm, measured at 10.degree. C. per minute, of about 161.degree. C. in both open and closed pans; characteristic X-ray diffractogram peaks at about 10.1, 12.1, 13.1, 14.3 degrees 2 theta; characteristic solid state .sup.13 C-NMR spectrum peaks at about 154.0, 148.5, 143.4, and 140.4 ppm, and

paroxetine hydrochloride anhydrate Form A comprises the following characteristics: a melting point of about 123.degree.-125.degree. C.; IR bands at about 513, 538, 571, 592, 613, 665, 722, 761, 783, 806, 818, 839, 888, 906, 924, 947, 966, 982, 1006, 1034, 1068, 1091, 1134, 1194, 1221, 1248, 1286, 1340, 1387, 1493, 1513, 1562, 1604, 3402, and 3631 cm.sup.-1 ; a DSC maximum endotherm, measured at 10.degree. C. per minute, of about 126.degree. C. in an open pan and about 121.degree. C. in a closed pan; characteristic X-ray diffractogram peaks at about 6.6, 8.0, 11.2, and 13.1 degrees 2 theta; characteristic solid state .sup.13 C-NMR spectrum peaks at about 154.3, 149.3, 141.6, and 138.5 ppm.

4. The process of claim 3 wherein the paroxetine hydrochloride anhydrate Form A is prepared by displacing the solvent in a paroxetine hydrochloride solvate with water.

5. A process for preparing paroxetine hydrochloride anhydrate Form C which comprises seeding a solution of paroxetine hydrochloride in an organic solvent with a seed crystal of paroxetine hydrochloride anhydrate Form C whereby crystallization of paroxetine hydrochloride anhydrate Form C occurs.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc